EGFR and cancer: As PAFR activation induces gefitinib and erlotinib (which inhibit the tyrosine kinase activity of the EGFR) induced MVP release [28], it is important to understand the insights into the interplay between the PAFR and EGFR axis in impacting cancer growth and/or efficacy of therapeutic agents, to devise novel approaches to improve therapy effectiveness.